{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 68,
  "pageCount": 132,
  "prevPage": 67,
  "nextPage": 69,
  "slideType": "customer_journey",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide uses a structured clinical case format to demonstrate drug efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/68",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-68",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.46,
        "x": 0.47,
        "y": 0.28
      },
      "kind": "callout",
      "text": "On-Study Activity: Started Tx: December 2020 (Remains On treatment*): Nemvaleukin monotherapy (6 µg/kg IV)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b97a2b2-f4a8-4f19-852f-c20771377c65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.46,
        "x": 0.47,
        "y": 0.73
      },
      "kind": "list",
      "text": "Treatment-related AEs: Manageable with no dose modifications; Anemia and fever, grade 2; Intermittent neutropenia grade 3 and grade 4",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26c39eff-9ade-44bb-bbfd-2f44d89e358d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.07,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "Diagnosis: Melanoma. Diagnosed December 13, 2016",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "924c06e1-8057-4b84-b6f7-918a47c5539a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*Patient continues on therapy as of March 15, 2021; +per RECIST criteria; ∓ Reported after the data cut off and awaiting confirmation. PD=progressive disease, SD=stable disease. Data cut off March 15, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b7d193c-3443-4a50-81ae-d0317ebf8f56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.43,
        "x": 0.07,
        "y": 0.5
      },
      "kind": "table",
      "text": "Prior Treatment table showing Line, Therapy, Duration, and Best Response.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8eb862a4-860a-4ced-9ef8-d7682abba1c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.46,
        "x": 0.47,
        "y": 0.47
      },
      "kind": "table",
      "text": "Change in Target Lesion from Baseline table showing Cycle 2 and Cycle 4 results.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecbf7812-060d-4837-9f35-acf96786555d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARTISTRY-1 Monotherapy Dose Expansion Cohort Case Study: 67-Year-old Male Cutaneous Melanoma Patient",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d683aa44-c896-4eef-8e3e-c85a461ef7e7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 69,
      "from": 55,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "59dd9c04-c6d4-46f5-9a3a-eaa6b3829180",
      "evidence": "Slides 55-69 detail the development and potential of Nemvaleukin alfa.",
      "position": 1,
      "objective": "To present Nemvaleukin alfa as a potential game-changer in cancer treatment",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.8,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}